Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
This study examines how patient trust in AID systems correlates with the perceived effectiveness of the system and how they alleviate diabetes management burdens.
Given that T1D patients share many of the same comorbidities as T2D patients, doctors have been prescribing them to T1D patients ‘off label’.
